How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 701–800 of 1,000
Chae, E., Yi, H., Choi, Y., Cho, H., Lee, K., & Moon, H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.023 · Cited by 24
Perspectives on the Discovery of Small-Molecule Modulators for Epigenetic Processes
Lu, Q., Quinn, A. M., Patel, M. P., Semus, S. F., Graves, A. P., Bandyopadhyay, D., Pope, A. J., & Thrall, S. H. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112437763 · Cited by 24
The Discovery of Medicines for Rare Diseases
Swinney, D. C., & Xia, S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.65 · Cited by 25
Self-citationThe Chemistry-Biology-Medicine Continuum and the Drug Discovery and Development Process in Academia
Nicolaou, K. C. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.020 · Cited by 30
Novel approaches to map small molecule–target interactions
Kapoor, S., Waldmann, H., & Ziegler, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.020 · Cited by 35
High-resolution phenotypic profiling of natural products-induced effects on the single-cell level
Kremb, S., & Voolstra, C. R. (2017) · Scientific Reports · doi:10.1038/srep44472 · Cited by 25
Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?
Bruyneel, A. A. N., McKeithan, W. L., Feyen, D. A. M., & Mercola, M. A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.07.003 · Cited by 27
Encircling the regions of the pharmacogenomic landscape that determine drug response
Fernández-Torras, A., Duran-Frigola, M., & Aloy, P. (2019) · Genome Medicine · doi:10.1186/s13073-019-0626-x · Cited by 22
Paciaroni, N. G., Norwood, V. M., Ratnayake, R., Luesch, H., & Huigens, R. W. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115546 · Cited by 25
High throughput generation of a resource of the human secretome in mammalian cells
Tegel, H., Dannemeyer, M., Kanje, S., Sivertsson, Å., Berling, A., Svensson, A.-S., Hober, A., Enstedt, H., Volk, A.-L., Lundqvist, M., et al. (2020) · New Biotechnology · doi:10.1016/j.nbt.2020.05.002 · Cited by 28
Natural products as probes in pharmaceutical research
Schmitt, E. K., Hoepfner, D., & Krastel, P. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-015-1691-9 · Cited by 24
The analysis of the market success of FDA approvals by probing top 100 bestselling drugs
Polański, J., Bogocz, J., & Tkocz, A. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9912-5 · Cited by 23
Dienone Compounds: Targets and Pharmacological Responses
Bazzaro, M., & Linder, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00812 · Cited by 23
Synthetic Macrocycles in Small-Molecule Drug Discovery
Vendeville, S., & Cummings, M. D. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00023-5 · Cited by 32
New Targets for Drug Discovery against Malaria
Santos, G., & Torres, N. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059968 · Cited by 31
The impact of molecular targets in cancer drug development: major hurdles and future strategies
Hebar, A., Valent, P., & Selzer, E. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.71 · Cited by 27
Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration
Cooper, D. J., Zunino, G., Bixby, J. L., & Lemmon, V. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.07.001 · Cited by 26
Newman, D. J., Cragg, G. M. L., & Kingston, D. G. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00005-5 · Cited by 35
Whole-organism phenotypic screening for anti-infectives promoting host health
Clatworthy, A. E., Romano, K. P., & Hung, D. T. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0018-3 · Cited by 24
The value of translational biomarkers to phenotypic assays
Swinney, D. C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00171 · Cited by 23
Self-citationSingh, R. K., & Najmi, A. K. (2018) · Current Drug Targets · doi:10.2174/1389450119666180816121323 · Cited by 24
Welzel, L., Twele, F., Schidlitzki, A., Töllner, K., Klein, P., & Löscher, W. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.02.010 · Cited by 25
Zulkipli, N. N., Rahman, S. A., Taib, W. R. W., Razali, R. M., Ismail, I., Ahmad, W. A. N. W., & Dahlan-Daud, C. K. (2024) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-024-00490-0 · Cited by 24
Precision cardiovascular medicine: shifting the innovation paradigm
Aikawa, M., Sonawane, A. R., Chelvanambi, S., Asano, T., Halu, A., Matamalas, J. T., Singh, S. A., Uchida, S., Aïkawa, E., Arenas, À., et al. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1474469 · Cited by 27
Evaluation of the Biological Activity of Compounds
Dougall, I. G., & Unitt, J. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00002-x · Cited by 23
Zebrafish-Based Screening Models for the Identification of Anti-Metastatic Drugs
Nakayama, J., & Makinoshima, H. (2020) · Molecules · doi:10.3390/molecules25102407 · Cited by 25
Hsueh, S., Luo, W., Tweedie, D., Kim, D. S., Kim, Y. K., Hwang, I., Gil, J.-E., Han, B., Chiang, Y. H., Selman, W. R., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00042 · Cited by 23
Abdullah, S., Mukherjee, S., ., S., & Debnath, B. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100386 · Cited by 30
Lee, J. A., Shinn, P., Jaken, S., Oliver, S. E., Willard, F. S., Heidler, S., Peery, R. B., Oler, J., Chu, S., Southall, N. T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130796 · Cited by 25
Schöttle, J., Chatterjee, S., Volz, C., Siobal, M., Florin, A., Rokitta, D., Hinze, Y., Dietlein, F., Plenker, D., König, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6276 · Cited by 22
Nanoparticle-Mediated Measurement of Target–Drug Binding in Cancer Cells
Ullal, A. V., Reiner, T., Yang, K. S., Gorbatov, R., Min, C., Issadore, D., Lee, H., & Weissleder, R. (2011) · ACS Nano · doi:10.1021/nn203450p · Cited by 27
Zhang, X., Deng, H., Xiao, Y., Xue, X., Ferrie, A. M., Tran, E., Liang, X., & Ye, F. (2014) · RSC Advances · doi:10.1039/c4ra03609c · Cited by 22
Radi, M., Evensen, L., Dreassi, E., Zamperini, C., Caporicci, M., Falchi, F., Musumeci, F., Schenone, S., Lorens, J. B., & Botta, M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.014 · Cited by 22
Identification of protein binding partners of small molecules using label-free methods
Saxena, C. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1227316 · Cited by 24
Vincetti, P., Kaptein, S. J. F., Costantino, G., Neyts, J. H., & Radi, M. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00583 · Cited by 22
Song, Y., Park, I.-S., Kim, J., & Seo, H. R. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.06.026 · Cited by 23
Immuno-detection by sequencing enables large-scale high-dimensional phenotyping in cells
van Buggenum, J. A. G. L., Gerlach, J. P., Tanis, S. E. J., Hogeweg, M., Jansen, P. W. T. C., Middelwijk, J., van der Steen, R., Vermeulen, M., Stunnenberg, H. G., Albers, C. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04761-0 · Cited by 24
Secretome-Based Screening in Target Discovery
Ding, M., Tegel, H., Sivertsson, Å., Hober, S., Snijder, A., Ormö, M., Strömstedt, P.-E., Davies, R., & Schiavone, L. H. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220917113 · Cited by 26
Jo, E., Jang, H., Shen, L., Yang, K. E., Jang, M. S., Huh, Y. H., Yoo, H.-S., Park, J., Jang, I., & Park, S.-J. (2020) · Integrative Cancer Therapies · doi:10.1177/1534735420923756 · Cited by 26
Spiros, Ä., Roberts, P., & Geerts, H. (2012) · Drug Development Research · doi:10.1002/ddr.21008 · Cited by 22
Phenotypic screening: the future of antibody discovery
Gonzalez-Munoz, A. L., Minter, R., & Rust, S. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.014 · Cited by 29
Anton, L., Cheng, W., Haile, M. T., Dziekan, J. M., Cobb, D. W., Zhu, X., Han, L., Li, E., Nair, A., Lee, C. L., et al. (2025) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01632-3 · Cited by 21
Frontiers in antibiotic alternatives for Clostridioides difficile infection
Phanchana, M., Harnvoravongchai, P., Wongkuna, S., Phetruen, T., Phothichaisri, W., Panturat, S., Pipatthana, M., Charoensutthivarakul, S., Chankhamhaengdecha, S., & Janvilisri, T. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i42.7210 · Cited by 24
Recent Advances in Divergent Synthetic Strategies for Indole-Based Natural Product Libraries
Kim, T., Ha, M. W., & Kim, J. (2022) · Molecules · doi:10.3390/molecules27072171 · Cited by 21
Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities
Rudd, S. G. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04562-3 · Cited by 24
Zhong, C., Zhu, R., Jiang, T., Tian, S., Zhao, X., Wan, X., Jiang, S., Chen, Z., Gong, R., He, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202305035 · Cited by 24
Ethological computational psychiatry: Challenges and opportunities
Monosov, I. E., Zimmermann, J., Frank, M. J., Mathis, M. W., & Baker, J. T. (2024) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102881 · Cited by 24
Gramowski, A., Schwertle, H.-J., Pielka, A.-M., Schultz, L., Steder, A., Jügelt, K., Axmann, J., & Pries, W. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00158 · Cited by 23
Kell, D. B. (2015) · Perspectives in Science · doi:10.1016/j.pisc.2015.06.004 · Cited by 23
Ye, F. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1020788 · Cited by 22
Molecular biodiversity and recent analytical developments: A marriage of convenience
Berkov, S. H., Mutafova, B., & Christen, P. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.04.005 · Cited by 24
Dudley, D. T., Li, X.-Y., Hu, C. Y., Kleer, C. G., Willis, A. L., & Weiss, S. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410996111 · Cited by 23
High‐Throughput RT‐PCR for Small‐Molecule Screening Assays
Bittker, J. A. (2012) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch110204 · Cited by 24
Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies
Molokanova, E., Mercola, M. A., & Savchenko, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.015 · Cited by 23
Kim, M., Hwang, Y. S., Cho, W., & Park, S. B. (2017) · ACS Combinatorial Science · doi:10.1021/acscombsci.7b00032 · Cited by 21
In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach
Ciallella, J. R., & Reaume, A. G. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.04.001 · Cited by 24
Novel triazine dimers with potent antitrypanosomal activity
Muthusamy, V., Salado, I. G., Heeres, J., Joossens, J., Lewi, P. J., Caljon, G., Maes, L. J. R. M., der Veken, P. V., & Augustyns, K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.075 · Cited by 21
Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins
Li, B. X., Chen, J., Chao, B., David, L. L., & Xiao, X. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00266 · Cited by 21
Luo, Y., Zeng, R., Guo, Q., Xu, J., Sun, X., & Wang, L. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob02193g · Cited by 21
Rodriguez, K. X., Howe, E. N., Bacher, E. P., Burnette, M. D., Meloche, J. L., Meisel, J. E., Schnepp, P. M., Tan, X., Chang, M., Zartman, J. J., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900266 · Cited by 21
Phenotypic screening techniques forCryptosporidiumdrug discovery
Love, M. S., & McNamara, C. W. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1812577 · Cited by 21
MNBDR: A Module Network Based Method for Drug Repositioning
Chen, H., & Zhou, X. (2020) · Genes · doi:10.3390/genes12010025 · Cited by 24
Zsidó, B. Z., Börzsei, R., Szél, V., & Hetényi, C. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00488 · Cited by 23
Computational approaches for innovative antiepileptic drug discovery
Talevi, A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1216965 · Cited by 23
Niazi, S. (2025) · Computational and Structural Biotechnology Reports · doi:10.1016/j.csbr.2025.100064 · Cited by 23
Microparticle-Assisted Precipitation Screening Method for Robust Drug Target Identification
Lyu, J., Ruan, C., Zhang, X., Wang, Y., Li, K., & Ye, M. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02756 · Cited by 20
Longwell, C. K., Hanna, S., Hartrampf, N., Sperberg, R. A. P., Huang, P., Pentelute, B. L., & Cochran, J. R. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00722 · Cited by 22
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
Morris, J., Kunkel, M. W., White, S. L., Wishka, D. G., Lopez, O. D., Bowles, L., Brady, P. S., Ramsey, P., Grams, J., Rohrer, T. N., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0267 · Cited by 22
Pathak, A. K., & Bandyopadhyay, T. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24533 · Cited by 20
Klinke, D. J. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0069-x · Cited by 21
In silicotools used for compound selection during target-based drug discovery and development
Caldwell, G. W. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1043885 · Cited by 25
A Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced Apoptosis
Sharlow, E. R., Leimgruber, S., Lira, A. K., McConnell, M. J., Norambuena, A., Bloom, G. S., Epperly, M. W., Greenberger, J. S., & Lazo, J. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00909 · Cited by 20
Novel drug discovery for Chagas disease
Moraes, C. B., & Franco, C. H. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1160883 · Cited by 20
Horn, M., Kroef, V., Allmeroth, K., Schuller, N., Miethe, S., Peifer, M., Penninger, J. M., Elling, U., & Denzel, M. S. (2018) · Oncotarget · doi:10.18632/oncotarget.24305 · Cited by 20
Williams, L. A., Joshi, V., Murphy, M., Ferrante, J., Werley, C. A., Brookings, T., McManus, O. B., Grosse, J., Davies, C. H., & Dempsey, G. T. (2019) · Neurochemical Research · doi:10.1007/s11064-018-2694-5 · Cited by 22
Weigle, S., Martin, E., Voegtle, A., Wahl, B., & Schuler, M. J. (2019) · Journal of Biological Methods · doi:10.14440/jbm.2019.285 · Cited by 21
Gruber, F. S., Johnston, Z. C., Barratt, C. L. R., & Andrews, P. D. (2020) · eLife · doi:10.7554/elife.51739 · Cited by 22
Lin, C., Wu, H., Hsu, Y., Cheng, T.-J. R., Liu, J., Huang, R.-J., Hsiao, T.-H., Wang, C.-J., Hung, P.-F., Lan, A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01783 · Cited by 21
Peppard, J., Rugg, C. A., Smicker, M. A., Powers, E. A., Harnish, E., Prisco, J., Cirovic, D. A., Wright, P. S., August, P. R., & Chandross, K. J. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114559490 · Cited by 21
Discovery and synthesis of novel Wogonin derivatives with potent antitumor activity in vitro
Wang, J., Ge, R., Qiu, X., Xu, X. J., Wei, L., Li, Z., & Bian, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.046 · Cited by 20
Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds
Tian, J., Vandermosten, L., Peigneur, S., Moreels, L., Rozenski, J., Tytgat, J., Herdewijn, P. A., den Steen, P. E. V., & Jonghe, S. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.004 · Cited by 20
Compound Functional Prediction Using Multiple Unrelated Morphological Profiling Assays
Rose, F., Basu, S., Rexhepaj, E., Chauchereau, A., Nery, E. D., & Genovesio, A. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630317740831 · Cited by 25
Roman, B. I., Ryck, T. D., Patronov, A., Slavov, S. H., Vanhoecke, B. W. A., KATRITZKY, A. R., Bracke, M., & Stevens, C. V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.029 · Cited by 20
Genetic Approaches to Facilitate Antibacterial Drug Development
Schnappinger, D. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021139 · Cited by 24
Setting Our Sights on Infectious Diseases
Rycker, M. D., Horn, D., Aldridge, B. B., Amewu, R. K., Barry, C. E., C, F. S. B. A., Cook, S., Ferguson, M. A. J., Gobeau, N., Herrmann, J. E., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00371 · Cited by 23
A Decade in a Systematic Review: The Evolution and Impact of Cell PaintingPreprint
Seal, S., Trapotsi, M., Spjuth, O., Singh, S., Puigvert, J. C., Greene, N., Bender, A., & Carpenter, A. E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.04.592531 · Cited by 26
A statistical framework for high-content phenotypic profiling using cellular feature distributions
Pearson, Y. E., Kremb, S., Butterfoss, G. L., Xie, X., Fahs, H., & Gunsalus, K. C. (2022) · Communications Biology · doi:10.1038/s42003-022-04343-3 · Cited by 19
Traditional Chinese Medicine and Clinical Pharmacology
Marshall, A. C. (2019) · Springer eBooks · doi:10.1007/978-3-319-56637-5_60-1 · Cited by 19
Daley, M. C. (2022) · ALTEX · doi:10.14573/altex.2109131 · Cited by 24
Electrical impedance myography detects age-related skeletal muscle atrophy in adult zebrafish
Rutkove, S. B., Callegari, S., Concepcion, H. A., Mourey, T., Widrick, J. J., Nagy, J. A., & Nath, A. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-34119-6 · Cited by 23
Lozano, E., Spina, R., Tonn, C. E., Sosa, M. A., & Cifuente, D. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.082 · Cited by 19
High-Throughput Screening Normalized to Biological Response: Application to Antiviral Drug Discovery
Patel, D. A., Patel, A. C., Nolan, W. C., Huang, G., Romero, A. G., Charlton, N., Agapov, E. V., Zhang, Y., & Holtzman, M. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113496848 · Cited by 20
Vignola‐Gagné, É., Rantanen, E., Lehner, D., & Hüsing, B. (2012) · Journal of Community Genetics · doi:10.1007/s12687-012-0130-0 · Cited by 20
Liggi, S., Drakakis, G., Koutsoukas, A., Cortés‐Ciriano, I., Martínez–Alonso, P., Malliavin, T. E., Velázquez‐Campoy, A., Brewerton, S. C., Bodkin, M. J., Evans, D. A. P., et al. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.137 · Cited by 21
Novel Screening Assay for the Selective Detection of G-Protein-Coupled Receptor Heteromer Signaling
van Rijn, R. M., Harvey, J. H., Brissett, D. I., DeFriel, J. N., & Whistler, J. L. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.198655 · Cited by 21
Forward Chemical Genetics in Yeast for Discovery of Chemical Probes Targeting Metabolism
St.Onge, R., Schlecht, U., Scharfe, C., & Evangelista, M. (2012) · Molecules · doi:10.3390/molecules171113098 · Cited by 23
Neural stem cells as tools for drug discovery: novel platforms and approaches
Gorba, T., & Conti, L. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.805199 · Cited by 21
Potential Strategies for Increasing Drug-Discovery Productivity
Cumming, J. G., Finlay, M. R. V., Giordanetto, F., Hemmerling, M., Lister, T., Sanganee, H. J., & Waring, M. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.7 · Cited by 20
Sundaramurthy, V., Barsacchi, R., Chernykh, M., Stöter, M., Tomschke, N., Bickle, M., Kalaidzidis, Y. L., & Zerial, M. (2014) · Nature Protocols · doi:10.1038/nprot.2014.027 · Cited by 22
One Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery
Chai, C. L. L., & Mátyus, P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.167 · Cited by 22
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.